GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Clinical trial NCT04535713 · UNKNOWN
Trial details
- NCT number
- NCT04535713
- Sponsor
- Sarcoma Oncology Research Center, LLC
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-30
- Primary completion
- 2025-09-30
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.